Kiniksa Pharmaceuticals Average 12-Month Price Target Raised to $99
Kiniksa's average price target rose from $98 to $99 across eight analysts, per TradingView, and the consensus rating stays at Buy.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the average 12-month price target for Kiniksa Pharmaceuticals International, plc rose from $98 to $99 per share. The estimate comes from eight analysts, whose forecasts range from $87 to $108 per share.
Based on the October 26 closing price, the updated target implies roughly 36% potential upside, according to the same report. All eight analysts covering the stock rate it Buy, with no Hold or Sell ratings.
why it matters
For markets this is a routine consensus update: a one-dollar increase in the average target suggests a small adjustment to estimates rather than a major shift. The data comes from FactSet and is provided for reference only, not as investment advice.
tags
instruments
sources
- Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $99, Implies 36% Upside — TradingView, 27 October 2026 at 19:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗